Abstract:Background: Programmed cell death ligand 1 (PD-L1) expression by immunohistochemistry (IHC) is a predictive factor for anti–PD-1/PD-L1 monoantibodies. However, intertumoral heterogeneity of PD-L1 expression and its accordance between resected tissue and biopsy tissue or cytological tumor samples remains controversial. Methods: A total of 72 patients who consecutively undergone primary lung cancer resection and were diagnosed as pulmonary adenosquamous carcinoma were included. PD-L1 expression level was assessed by IHC (PD-L1: Clone E1L3N; Cell Signaling #13684) in different histological component of both primary and lymph node tissues respectively. Results: With a 5% of cutoff, PD-L1 expression was 20.8%, 33.3% in adenomatous and squamous cell component respectively. When various cutoffs including 0.01, 0.05, 0.10 were used, the PD-L1 expression was discrepant in 26.4%, 19.4%, 12.5% cases respectively. With combination of the expression in tumor cells (TC) and tumor-infiltrated lymphocytes (TILs), discrepancies between two histological components were observed in 13.9%, 22.2%, 30.6% cases repectively. Of 38 lymphatic metastasis cases, there were 4 types of lymphatic node histology including adenocarcinoma, squamous cell, adenosquamous and a mixture of above. By different histological component and cutoff value, the concordances of PD-L1 expression were in 74.1%, 80.0%, 88.9% cases for adenomatous cell component and 90.0%, 80.0%, 85.0% cases for squamous cell component respectively. In addition, the discrepancy of adenocarcinoma histological subtype accounts for the lower concordant rate in adenomatous component.Table: 396OTable 1.1 PD-L1 difference between adenomatous and squamous componentscutoff valuePD-L1 expression in TC in primary tumor siteconcordance (%)adenomatous component PD-L1+ n (%)squamous cell component PD-L1+ n(%)kappa0.0173.632 (44.4)39 (54.2)0.4770.0580.615 (20.8)24 (33.3)0.5270.1087.56 (8.3)11 (15.3)0.407Table 1.2 PD-L1 heterogeneity between adenomatous and squamous components based on tumor cells and TILscutoff valuePD-L1 expression in TC and TILs in primary tumor siteconcordance (%)adenomatous component PD-L1+ n(%)squamous cell component PD-L1+ n(%)kappa0.0169.447(65.3)45(62.5)0.3380.0577.820(27.8)26(36.1)0.4930.1086.17(9.7)11 (15.3)0.370Table 1.3 PD-L1 difference in TC between primary tumor site and lymphatic metastasiscut off valueadenomatous component n = 27squamous cell component n = 20concordanceprimary tumor PD-L1+ n(%)nodal metastasis PD-L1+ n (%)kappaconcordanceprimary tumor PD-L1+ n(%)nodal metastasis PD-L1+ n (%)kappa0.0177.814 (51.9)12 (44.4)0.55790.012 (60.0)12 (60.0)0.7920.0574.19 (33.3)6 (22.2)0.36480.09 (45.0)9 (45.0)0.5960.1088.94 (14.8)3 (11.1)0.50985.05 (25.0)4 (20.0)0.571 Open table in a new tab Conclusions: PD-L1 expression showed a high discrepancy among adenomatous component and squamous cell components. In contrast, PD-L1 was highly consistent between paired histological types of lymph node and the primary lesion, which may suggest that the intrinsic genomic features plays important role in the PDL1 heterogeneously expression. Legal entity responsible for the study: Tongji Pulmonary Hospital, Tongji University Funding: Shanghai Municipal Education Commission Disclosure: All authors have declared no conflicts of interest.

Concordance of PD-L1 combined positive score (CPS) analysis between primary gastric cancer and matched peritoneal metastasis.

Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis.

Concordance among the Three Commercially Available PD-L1 Assays for Esophageal Squamous Cell Carcinoma

Assessment of programmed death-ligand 1 expression in primary tumors and paired lymph node metastases of gastric adenocarcinoma

Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer

The Heterogeneity of PD-L1 Expression among the Different Histological Components and Metastatic Lymph Nodes in Patients with Resected Lung Adenosquamous Carcinoma

Discordance of PD-L1 Expression in Primary and Metastatic Ovarian High-Grade Serous Carcinoma and Its Correlation with CD8 + Tumor-Infiltrating Lymphocytes and Patient Prognosis

Concordance of PD-L1 Status Between Image-Guided Percutaneous Biopsies and Matched Surgical Specimen in Non-Small Cell Lung Cancer

Comparison of 22C3 PD-L1 Expression Between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer

Association of the programmed death ligand‐1 combined positive score in tumors and clinicopathological features in esophageal cancer

PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays

P1.04-05 PD-L1 Expression (SP263) in Lung Cancer and Paired Brain Metastases – A Single Center Study in 211 Patients

Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.

Concordance of PD-L1 Expression in Metastatic Triple-negative Breast Cancer Between the 22C3 and E1L3N Antibodies Using Combined Positive Scoring

Impact of PD-L1 expression on survival in patients with unresectable/recurrent gastric cancer receiving first-line chemotherapy without immune checkpoint inhibitors.

Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma

Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.

PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores

Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey

Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis

Comparative Study Between Image-Guided Percutaneous Biopsies and Matched Surgical Specimens for the Evaluation of PD-L1 Status in Non-Small Cell Lung Cancer.